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Valorisation
Lower urinary tract dysfunctions are a major global health issue. The studies presented in this
thesis have aimed to identify new treatment targets. Detailed knowledge of urinary bladder
signalling is of utmost importance when new treatment targets have to be identified. Until now,
it is not fully known how the different signalling systems, involved in regulation of micturition
and continence, interact with each other. Two important bladder dysfunctions have been
discussed in this thesis i.e. the overactive bladder syndrome and detrusor underactivity. These
two dysfunctions will be elaborated to elucidate the societal impact of the presented research. 
The overactive bladder syndrome (OAB) is defined as urgency, usually with frequency and
nocturia, with or without urgency urinary incontinence
1,2
. It is a highly prevalent condition with
almost 100 million people affected in the western world, 33 million in the United States
3 
and 66 
million in the European Union
4
. The impact on patients’ quality of life is enormous and even
higher than the impact on quality of life associated with diabetes
5-8
. Furthermore, the economic 
costs and burden of OAB are comparable to those of rheumatoid arthritis and asthma
9
. The
pathophysiology is multifactorial and the patient group shows a high heterogeneity. Therefore,
optimal therapy remains challenging. To optimize bladder function in those patients, two
aspects are of importance: the heterogeneity of OAB needs to be taken into account.
Furthermore we need to more knowledge about symptomatology-related physiological 
processes taking place at bladder level. Concerning the heterogeneity of OAB, patient 
subgroups have to be identified and the pathological functional and morphological derivatives
have to be investigated for each subgroup. Concerning the aspect on bladder physiology, the
question to put forward is: How do the different signalling systems interact with each other and
what will be the effect of bladder dysfunction on those interactions? Answering these questions
will enable us to identify new, more specific treatment targets for OAB.
Currently, antimuscarinic drugs are widely used to treat patients suffering from OAB. However,
the effect has been shown to be small compared to placebo, with a high prevalence of side
effects
10
. This signifies the need for new pharmacological treatment targets. The question is: 
Can we use other signalling systems, which are active in the bladder to modify excitation– 
contraction coupling? In studies presented in chapter 4 and 5, the prostanoid system was
identified to be a potential candidate for the modulation of muscarinic induced contractions. 
143
  
           
  
             
          
            
         
         
        
        
        
      
        
        
 
         
       
      
              
       
        
          
           
          
        
         
 
            
       
      
          
 
Valorisation
Future research can elaborate on our data and might help to identify new treatment targets
with less side effects for the patients. 
The second bladder dysfunction that may benefit from the results of this thesis, is detrusor
underactivity. In older women, the prevalence of detrusor underactivity ranges from 12%-45%.
In males, a prevalence between 9% and 45% has been identified dependent on population and
diagnostic criteria
11
. One of the causes of detrusor underactivity is bladder outlet obstruction,
which will induce a cascade of morphological and functional changes within the bladder wall. At
a later stage, these changes can lead to detrusor underactivity. The most frequently occurring 
cause of bladder outlet obstruction in men, is prostate enlargement due to Benign Prostatic 
Hyperplasia. In addition, functional neurogenic and even psychogenic causes may also underlie
the detrusor underactivity
12
. Detrusor underactivity and the subsequent bladder distension give
rise to residual urine after voiding in males and females resulting, in a significant burden: 
Chronic urinary tract infections, increased antibiotic resistance of microorganisms, reduced
quality of life and high costs for care, especially in the institutionalised elderly.
Currently, there is no treatment option for detrusor underactivity with good long-term results. 
The current management includes life-long intermittent catheterisation, which is the only
option to prevent urinary tract morbidity. Unfortunately, performing intermittent
catheterisation has a large impact on the quality of life
13
. It is of utmost importance to
understand the pathophysiological processes, which lead to detrusor underactivity. This thesis
contains a literature review on detrusor underactivity, that identifies potentially new treatment 
targets and could serve as a base for future research. Current knowledge is presented, on
possible changes in physiological processes that may lead to detrusor underactivity. To find new
treatment modalities, more basic and clinical research is needed. Patient subgroups have to be
identified, and pathophysiological processes involved in the development of detrusor
underactivity have to be elucidated. Hereby, novel treatment strategies can be developed,
improving patients’ quality of life.
The studies presented in this thesis focussed on the interaction of signalling systems. The
prostanoid system was identified as a potential target system when searching for new
therapeutical strategies. Therefore, a first step was provided towards new therapeutical
approaches using pharmacological modulators of the prostanoid system for the treatment of
bladder dysfunctions.
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